GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Fatty Acid Biosynthesis Disorders overview

Fatty acid biosynthesis disorders (FABDs) are a group of inherited metabolic disorders that affect the ability of the body to use fatty acids as a source of energy. Fatty acids are long chains of carbon and hydrogen atoms that are stored in fat cells and can be broken down to produce energy when glucose (sugar) is not available. However, people with FABDs have defects in the enzymes or transport proteins that are involved in the process of fatty acid breakdown, also called fatty acid oxidation. This leads to a buildup of fatty acids or their byproducts in the blood and tissues, and a shortage of energy for the cells. FABDs can cause various symptoms depending on the type and severity of the disorder, such as low blood sugar, muscle weakness, heart problems, liver enlargement, brain damage, and developmental delays. FABDs are diagnosed by newborn screening tests, genetic tests, or biochemical tests that measure the levels of fatty acids or their metabolites in the blood or urine. Treatment of FABDs depends on the specific disorder, but usually involves dietary modifications, supplements, medications, and avoiding fasting or prolonged exercise. FABDs are rare disorders that affect about 1 in 10,000 to 50,000 people worldwide.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.